”The first choice of treatment for solid tumors such as gastric cancer is surgery, which must remove the local lesions as soon as possible, and then give scientific radiotherapy and chemotherapy as adjuvant treatment. In the past, we met many patients whose surgery was very successful and chemotherapy was administered after surgery, but the survival time of the patients was not significantly extended. Dr. Fengwei Wang, a radiation oncologist, said that the 5-year survival rate of patients with mid- to late-stage gastric cancer is not significantly improved when only chemotherapy is given before or after surgery. Dr. Wang said that there are two main reasons for failure of gastric cancer: regional recurrence in and around the stomach, and metastasis. Successful surgery is a condition for long-term patient survival, but not a guarantee for long-term survival. Due to the local invasive nature of mid- to late-stage tumors and the high metastasis of surrounding lymph nodes, it is difficult to remove all the remaining cancer cells around the primary lesion, surrounding metastatic lymph nodes, peritoneal dissemination and implanted cancer cells with human eyes during surgery. Furthermore, abdominal organs such as stomach, liver and pancreas are supplied with blood by portal vein, and the blood return flow has to pass through liver, so the possibility of hematogenous metastasis is also higher. Therefore, recurrence and metastasis after surgery of middle and late stage tumors are the main reasons for tumor treatment failure, and effective control of cancer recurrence and metastasis is fundamental to prolong patients’ survival time. Dr. Wang said that the 5-year survival rate of mid- to late-stage gastric cancer is about 40% with surgery alone. Most of the pathological types of gastric cancer are adenocarcinoma, and it is difficult to completely eradicate large tumors by radiotherapy alone; however, the residual cancer cells around the primary lesion, surrounding metastatic lymph nodes, peritoneal dissemination and implanted cancer cells are relatively sensitive to the simultaneous integrated treatment of radiotherapy and chemotherapy, which increases the chance of complete eradication of tumors. Before and after surgery, gastrointestinal surgery specialists and radiotherapy specialists work together to study a set of scientific integrated treatment plan, and then receive surgery followed by simultaneous radiotherapy. Radiation therapy can rapidly kill the remaining cancer cells locally and improve the local control rate. Chemotherapy can control the distal metastasis of cancer cells and kill potential metastases. For the treatment of gastric cancer, radiation therapy and chemotherapy work in synergy to improve each other’s therapeutic effect and achieve the effect of 1+1 >2. Compared with single surgery, the 4-year survival rate can be increased by more than 9%, reaching nearly 50%. In response to people’s concern about the side effects of radiotherapy, Dr. Wang said that on the one hand, with the improvement of technology, the technology of radiotherapy is also improving. At the same time, the emergence of a large number of adjuvant drugs has reduced or eliminated most of the reactions to radiotherapy, and radiotherapy for most patients can be treated in outpatient clinics, such as gastrointestinal reactions and bone marrow suppression, which have long been a concern for oncologists, and should not be a problem for patients to receive regular radiotherapy. On the contrary, what makes us saddened in clinical practice is that patients do not receive formal treatment measures and take “panacea or blood bun”, which causes delay in the disease. For the persistent disease of gastric cancer, medical practitioners are willing to work together with their colleagues and keep working hard to stand in the forefront of tumor treatment as soon as possible.